In this OncLive Insights program, Dr. Mark Dailey, Dr. Caron A. Jacobson, and NP Stefanie Sigmund discuss strategies to improve access to chimeric antigen receptor (CAR) T-cell therapy and coordinate care for patients with diffuse large B-cell lymphoma (DLBCL). The discussion explores identifying appropriate candidates for CAR T-cell therapy, initiating timely referrals, and addressing misconceptions about eligibility, including considerations for older patients and those with comorbidities. The panel examines communication between community oncology practices and academic CAR T-cell centers, management of patients awaiting treatment, and barriers related to travel, lodging, finances, and caregiver support. Additional topics include bridging therapy, outpatient treatment pathways, post-infusion monitoring, and the implications of the FDA’s 2025 elimination of Risk Evaluation and Mitigation Strategies (REMS) requirements. The experts also discuss structured care transitions, monitoring for late complications, long-term follow-up, and a potential hub-and-spoke model to strengthen collaboration and reduce the burden on patients and caregivers.
In this segment, Dr. Mark Dailey, Dr. Caron A. Jacobson, and NP Stefanie Sigmund introduce the challenges of coordinating chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large B-cell lymphoma (DLBCL), particularly those who must travel long distances to specialized treatment centers.
- In this segment, Dr. Caron A. Jacobson discusses strategies to streamline referrals for chimeric antigen receptor (CAR) T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL). She emphasizes the importance of understanding how CAR T-cell services are organized at the receiving institution, as referral pathways may differ across centers.
